Top stories in gastroenterology: Legalized cannabis fails to increase hyperemesis syndrome rates, oral vancomycin assists with ulcerative colitis remission

All last week’s top stories in gastroenterology were from Healio’s live coverage of Digestive Disease Week, which recently wrapped up in San Diego. They included a study that found oral vancomycin safely induced and maintained remission of ulcerative colitis among a certain subset of patients and research that suggested states that have legalized cannabis did not experience higher hospitalization rates for cannabis hyperemesis syndrome vs. states where the substance is still illegal.

Other highlights were two presentations that indicated upadacitinib produced dose-dependent results in moderate-to-severe ulcerative colitis despite previous biologic failures, data that suggested Stelara was effective for the induction and maintenance treatment of patients with moderate-to-severe ulcerative colitis regardless of biologic history, a report that concluded that students with inflammatory bowel disease have trouble adjusting to college. – by Melissa J. Webb

Increased use drives cannabis hyperemesis syndrome rates, not legalization

States with legalized cannabis have not seen higher hospitalization rates for cannabis hyperemesis syndrome compared with other states, a speaker said. Read more.

Oral vancomycin induces, maintains remission of ulcerative colitis in patients with ulcerative colitis and primary sclerosing cholangitis

Oral vancomycin safely induced and maintained remission of ulcerative colitis among a subset of patients with ulcerative colitis and associated primary sclerosing cholangitis, including those who had undergone liver transplantation, according to a study results. Read more.

Upadacitinib shows mucosal healing in ulcerative colitis biologic failures, responders

A new JAK inhibitor, upadacitinib, produced dose-dependent results in moderate-to-severe ulcerative colitis despite previous biologic failures, according to two presentations. Read more.

Stelara effective for induction, maintenance of ulcerative colitis regardless of biologic history

Stelara was effective for the induction and maintenance treatment of patients with moderate-to-severe ulcerative colitis whether or not they previously failed biologic therapy, according to study data. Read more.

Students with inflammatory bowel disease have trouble adjusting to college

Starting college can be tough for anyone, but students with inflammatory bowel disease have a greater risk for poor adjustment to college life, a speaker said. Read more.